Boucher & Muir - Ferropods

Therapeutic Goods Act 1989

Approval under section 42DF for use of restricted representations by Boucher & Muir Pty Ltd

I, Leanne McCauley, as a delegate of the Secretary to the Department of Health, on receipt of an application from Boucher & Muir Pty Ltd, have approved under section 42DF of the Therapeutic Goods Act 1989 (the Act) the restricted representations described in paragraph (A) below for use in advertisements directed to consumers, for the product identified in paragraph (B):

1. Indication Statements:

   1. For the prevention and treatment of iron deficiency anaemia.
   2. May help relive fatigue associate with iron and vitamin C deficiency where dietary intake is inadequate.

   Diagnosis Statement:

   For use when iron deficiency or iron deficiency anaemia has been diagnosed by the doctor and a therapeutic iron supplement is recommended.

   On the basis that when the Indication Statements in (i) or (ii) above are used in advertisements, other than the label, then:

   • the Diagnosis Statement must also be used; and
   • the Diagnosis Statement must be displayed with equal or greater prominence than the Indication Statement.
2.  
   • Ferropods AUST R 329091

Dated this 9th day of January 2021

Signed electronically

Leanne McCauley
Delegate of the Secretary to the Department of Health
Advertising Compliance Unit
Regulatory Compliance Branch